Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia
Archives of Internal MedicinePublished 25 July 1994
D. Roger Illingworth
Citations128
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Lovastatin was better tolerated than niacin and both exerted favorable dose-dependent changes on the concentrations of plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
Abstract
Lovastatin and niacin both exerted favorable dose-dependent changes on the concentrations of plasma lipids and lipoproteins. Lovastatin was more effective in reducing LDL cholesterol concentrations, whereas niacin was more effective in increasing high-density lipoprotein cholesterol concentrations and reducing the Lp(a) lipoprotein level. Lovastatin was better tolerated than niacin, in large part because of the common cutaneous side effects of niacin.
Keywords
Medicine
Archives of Internal MedicineReport of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
2,298 Citations1988DeWitt S. Goodman
New guidelines for the treatment of high blood cholesterol in adults 20 years of age and over are provided and which patients should go on to have lipoprotein analysis, and which should receive cholesterol-lowering treatment on the basis of their low density lipop protein levels and status with respect to other coronary heart disease risk factors are detailed.
New England Journal of MedicineRegression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B
2,166 Citations1990Greg Brown, John J. Albers +8 more
In men with coronary artery disease who were at high risk for cardiovascular events, intensive lipid-lowering therapy reduced the frequency of progression of coronary lesions, increased the frequencyof regression, and reduced the incidence of cardiovascular events.
Journal of the American College of CardiologyFifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
1,841 Citations1986Paul L. Canner, Kenneth G. Berge +5 more
The Coronary Drug Project was conducted to assess the long-term efficacy and safety of five lipid-influencing drugs in 8,341 men aged 30 to 64 years with electrocardiogram-documented previous myocardial infarction, and niacin treatment showed modest benefit in decreasing definite nonfatal recurrent myocardia but did not decrease total mortality.
JAMABeneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts
1,643 Citations1987David H. Blankenhorn
The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol hydrochloride and niacin therapy in 162 nonsmoking men aged 40 to 59 years with previous coronary bypass surgery.
Journal of Lipid ResearchA comprehensive evaluation of the heparin–manganese precipitation procedure for estimating high density lipoprotein cholesterol
1,259 Citations1978G. Russell Warnick, J J Albers
The present heparin-Mn(2+) procedure was found to be reasonably specific and not often subject to large errors; however, 9% (primarily hypertriglyceridemic samples) of the 966 plasma samples treated with heparin-Mn(2+) had obvious supernatant turbidity, indicating incomplete sedimentation of apoB-associated lipoproteins.
New England Journal of MedicineHMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
762 Citations1988John A. Oates, Alastair J.J. Wood +1 more
If reductase inhibitors prove to be free of long-term adverse effects, they will undoubtedly be used widely for treating hypercholesterolemia and this review will examine lovastatin.
Annals of Internal MedicineCoronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)
640 Citations1993David H. Blankenhorn, Stanley P. Azen +10 more
In the Cholesterol Lowering Atherosclerosis Study (CLAS), it was shown that diet in conjunction with colestipol and niacin therapy had a beneficial effect on coronary artery lesions at 2 and 4 years based on the global change score [5, 15] and at 2 yearsbased on quantitative coronary angiography [16]; CLAS was the only angiographic trial to have used both the findings of quantitative coronaryAngiography and theglobal change score as end points.
New England Journal of MedicineRelation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia
591 Citations1990Mary Seed, Fritz Hoppichler +5 more
An elevated level of lipop protein(a) is a strong risk factor for CHD in patients with familial hypercholesterolemia, and the increase in risk is independent of age, sex, smoking status, and serum levels of total cholesterol, triglyceride, or high-density lipoprotein cholesterol.
Journal of Clinical InvestigationLipoprotein (a). Heterogeneity and biological relevance.
581 Citations1990A M Scanu, G M Fless
This work will examine the various aspects of this heterogeneity exhibited by this lipoprotein particle and attempt to provide a global view on past and current knowledge on Lp(a) and identify those controversial areas where intensified research efforts are likely to provide important new advances.
JAMAA Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction
499 Citations1993Paul M. Ridker
The data do not support the use of Lp(a) level as a screening tool to define cardiovascular risk among this population of predominantly middle-aged white men, and no evidence of association between Lp-a level and risk of future MI is found.
Archives of Internal MedicineExpanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
484 Citations1991Reagan H. Bradford
Lovastatin, when added after an adequate trial of a prudent diet, is a highly effective and generally well-tolerated treatment for patients with moderate hypercholesterolemia.
Journal of Internal MedicinePronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid
447 Citations1989Lars A. Carlson, Anders Hamsten +1 more
Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid is reported.
BMJCholesterol lowering and mortality: the importance of considering initial level of risk.
428 Citations1993George Davey Smith, Fujian Song +1 more
Currently evaluated cholesterol lowering drugs seem to produce mortality benefits in only a small proportion of patients at very high risk of death from coronary heart disease, and future trials should aim to clarify the level of risk above which treatment is of net benefit.
AtherosclerosisLevels of lipoprotein Lp(a) decline with neomycin and niacin treatment
264 Citations1985Arzu R. Gürakar, Jeffrey M. Hoeg +3 more
Observations indicate that lipop protein Lp(a) concentrations can be altered pharmacologically and that the progression of cardiovascular disease may be altered through changes in lipoprotein (a) levels.
Journal of Clinical InvestigationEffects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A Metabolism
249 Citations1979James Shepherd, Christopher J. Packard +3 more
The data suggest that the effects of nicotinic acid on the HDL subfraction distribution may be mediated via (a) net transfer of ApoA-I from HDL(3) to HDL(2) and (b) a reduction in ApOA-II synthesis.
MetabolismContrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
233 Citations1985Robert H. Knopp, Janice Ginsberg +7 more
This study compares the effects of time-release niacin with those of unmodified niacIn on lipoprotein lipids, including HDL2 and HDL3, apoproteins A-I and A-II, clinical chemistries, symptomatic side effects, and adherence to the medication regimen
JAMALipoprotein(a). A genetic risk factor for premature coronary heart disease
228 Citations1992A M Scanu
Annals of Internal MedicineFulminant Hepatic Failure after Ingestion of Sustained-Release Nicotinic Acid
119 Citations1989Gerard E. Mullin, Joel K. Greenson +1 more
Nicotinic acid is an effective, widely used treatment for hypercholesterolemia and Hepatotoxicity is a rare complication of therapy, which usually occurs with ingestion of more than 3 g of the substance per day.
Arteriosclerosis and Thrombosis A Journal of Vascular BiologyComparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study.
92 Citations1991Yoshiro Saito, S. Yoshida +3 more
When simvastatin was administered orally once per day in the evening, it reduced cholesterol levels to a significantly greater degree than when it was given in the morning.
The American Journal of CardiologyEffect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio
81 Citations1989James Alderman, Richard C. Pasternak +4 more
Niacin can be administered in a fashion that is well tolerated, inexpensive and very effective in improving the cholesterol to HDL ratio.
Journal of the American Statistical AssociationThe Wilcoxon, Ties, and the Computer
81 Citations1966Jerome Klotz
It is regretted that in small to moderate sample sizes, no consistent improvement over the simple normal approximation was found and the erratic nature of both the values and jumps of the distribution appears to rule out any good, smooth approximation in small samples.
Clinical ChemistryEnzyme-linked immunoabsorbant assay of apolipoprotein AII in plasma, with use of a monoclonal antibody.
72 Citations1986Evan A. Stein, Linda P. DiPersio +5 more
A monoclonal antibody to human apolipoprotein (Apo) AII is produced and used in an enzyme-linked immunoabsorbant assay (ELISA) for Apo AII in human plasma and lipoprotein subfractions and correlated well with those by a polyvalent-antisera-based RIA procedure.
Archives of Internal MedicineStudies of Nicotinic Acid Use in Hypercholesteremia
72 Citations1961William Barclay Parsons
Numerous reports have verified reduction of serum cholesterol levels in human hypercholesterolemia by large doses of nicotinic acid, and it has become increasingly apparent that this is the most effective chemotherapeutic agent presently available for this purpose.
JAMANicotinic Acid Treatment of Hypercholesteremia
70 Citations1961Norman A. Christensen
The most significant difference was the greater frequency and severity of side effects during treatment with the 3 sustained-action preparations, and this precluded the majority of patients from completing a 3-month period of treatment.
Archives of Internal MedicineEffects of Simvastatin and Cholestyramine in Familial and Nonfamilial Hypercholesterolemia
64 Citations1990Evan A. Stein
Simvastatin was better tolerated than cholestyramine, which had numerous gastrointestinal tract side effects, and no patient had a serious drug-related adverse event.
Archives of Internal MedicineEffect of Low-Dose Niacin on High-Density Lipoprotein Cholesterol and Total Cholesterol/High-Density Lipoprotein Cholesterol Ratio
58 Citations1988Myron H. Luria
Although often difficult to administer to patients, niacin deserves consideration as an inexpensive agent especially useful for elevating HDL cholesterol level and altering the total cholesterol/HDL cholesterol ratio.
The American Journal of CardiologyA multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia
55 Citations1993The Lovastatin Pravastatin Study Group∗
Across the recommended dosage ranges, lovastatin was more effective than pravastatin in reducing total and LDL cholesterol; however, both agents had similar safety profiles.
AtherosclerosisComparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles
33 Citations1988Eero Helve, Matti J. Tikkanen
Analysis of LDL composition demonstrated that the LDL-cholesterol lowering effect of probucol in FH was entirely due to reduction in the proportion of cholesterol in LDL with no reduction in LDL mass.
Journal of Internal MedicineEffects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL<sup>2</sup>, and HDL<sup>3</sup>, in hyperlipoproteinaemia
27 Citations1990Gustaf Wahlberg, Göran Walldius +2 more
The results suggest that, in man, this reaction is stimulated in vivo by prolonged nicotinic acid therapy, which is proposed, on the basis of in vitro data, that HDL, is formed from HDL, particles in the blood.
AtherosclerosisThe effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidaemic subjects
22 Citations1990Jan Johansson, Lars A. Carlson
Recent studies suggest that the profound increase of HDL-2b levels by nicotinic acid treatment in hyperlipidaemic patients might be of considerable importance in the protection of coronary atherosclerosis.
Annals of the Institute of Statistical MathematicsCombining independent one-sample tests of significance
19 Citations1967Madan L. Puri
Mayo Clinic ProceedingsLow-Dose, Time-Release Nicotinic Acid: Effects in Selected Patients With Low Concentrations of High-Density Lipoprotein Cholesterol
18 Citations1992Ray W. Squires, Thomas G. Allison +3 more
In a retrospective analysis, 63 participants in a cardiac rehabilitation-preventive cardiology program were identified as having low blood concentrations of high-density lipoprotein cholesterol (HDL-C) and a mean total cholesterol level of 223 mg/dl after 3 months of hygienic measures designed to increase the HDL-C level.